Windlas Biotech Approves FY26 Results, Recommends ₹6.30 Dividend

Windlas Biotech Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹6.30 per equity share of face value ₹5, subject to shareholder approval at the upcoming Annual General Meeting. The auditors, J C Bhalla & Co, issued unmodified opinions on the audited financial results. The board meeting commenced at 2.45 P.M. and concluded at 4.20 P.M.